Litcius/Paper detail

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, Shogo Nomura, Hiroshi Katayama, Tomoko Kataoka, Akiko Todaka, Hiroaki Yanagimoto, Soichiro Morinaga, Shogo Kobayashi, Kazuaki Shimada, Yu Takahashi, Toshio Nakagohri, Kunihito Gotoh, Ken Kamata, Yasuhiro Shimizu, Makoto Ueno, Hiroshi Ishii, Takuji Okusaka, Junji Furuse, Keiya Okamura, Yasuyuki Kawamoto, Akio Katanuma, Michiaki Unno, Hirofumi Shirakawa, Hironori Yamaguchi, Amane Takahashi, Masafumi Ikeda, Hiroo Yanagibashi, Naoya Kato, Takuji Okusaka, Yoshihiro Sakamoto, Yasushi Kojima, Ryota Higuchi, Naoki Sasahira, Keiji Sano, Toshio Nakagohri, Yu Sunakawa, Soichiro Morinaga, Yusuke Kumamoto, Kazuya Sugimori, Tatsuya Nomura, Kazuto Shibuya, Isamu Makino, Kentaro Yamazaki, Nobumasa Mizuno, Ken Kamata, Hiroshi Wada, Kunihito Gotoh, Mitsugu Sekimoto, Tetsuo Ajiki, Ikuo Nakamura, Ikuya Miki, Hiroaki Nagano, Koji Ohta, Takehiro Okabayashi, Masayuki Furukawa, Nao Fujimori

2023The Lancet234 citationsDOI

Topics & Concepts

MedicineClinical endpointGallbladder cancerInternal medicineGallbladderClinical trialSurgeryAdverse effectIntention-to-treat analysisGastroenterologyCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersLiver Diseases and Immunity
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial | Litcius